1. Home
  2. IAF vs ELTX Comparison

IAF vs ELTX Comparison

Compare IAF & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IAF
  • ELTX
  • Stock Information
  • Founded
  • IAF 1985
  • ELTX 2011
  • Country
  • IAF United States
  • ELTX United States
  • Employees
  • IAF N/A
  • ELTX N/A
  • Industry
  • IAF Finance/Investors Services
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IAF Finance
  • ELTX Health Care
  • Exchange
  • IAF Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • IAF 110.7M
  • ELTX 121.7M
  • IPO Year
  • IAF N/A
  • ELTX N/A
  • Fundamental
  • Price
  • IAF $4.03
  • ELTX $4.95
  • Analyst Decision
  • IAF
  • ELTX Strong Buy
  • Analyst Count
  • IAF 0
  • ELTX 3
  • Target Price
  • IAF N/A
  • ELTX $9.50
  • AVG Volume (30 Days)
  • IAF 90.4K
  • ELTX 39.4K
  • Earning Date
  • IAF 01-01-0001
  • ELTX 03-31-2025
  • Dividend Yield
  • IAF 11.44%
  • ELTX N/A
  • EPS Growth
  • IAF N/A
  • ELTX N/A
  • EPS
  • IAF N/A
  • ELTX N/A
  • Revenue
  • IAF N/A
  • ELTX N/A
  • Revenue This Year
  • IAF N/A
  • ELTX N/A
  • Revenue Next Year
  • IAF N/A
  • ELTX N/A
  • P/E Ratio
  • IAF N/A
  • ELTX N/A
  • Revenue Growth
  • IAF N/A
  • ELTX N/A
  • 52 Week Low
  • IAF $3.60
  • ELTX $3.34
  • 52 Week High
  • IAF $4.59
  • ELTX $11.45
  • Technical
  • Relative Strength Index (RSI)
  • IAF 39.85
  • ELTX 23.49
  • Support Level
  • IAF $3.98
  • ELTX $7.54
  • Resistance Level
  • IAF $4.10
  • ELTX $8.13
  • Average True Range (ATR)
  • IAF 0.05
  • ELTX 0.55
  • MACD
  • IAF 0.01
  • ELTX -0.29
  • Stochastic Oscillator
  • IAF 61.09
  • ELTX 1.02

About IAF abrdn Australia Equity Fund Inc.

Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: